Phathom Pharmaceuticals Management
Management criteria checks 1/4
Phathom Pharmaceuticals' CEO is Steve Basta, appointed in Apr 2025, has a tenure of less than a year. directly owns 0.16% of the company’s shares, worth $1.97M. The average tenure of the management team and the board of directors is 0.6 years and 4.7 years respectively.
Key information
Steve Basta
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | less than a year |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
Nov 21Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Jul 19
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
Jun 02
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Apr 18Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Dec 11Following Up On Phathom Pharmaceuticals
Sep 03Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Jun 26Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
Mar 18Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30
Aug 02CEO
Steve Basta (59 yo)
Mr. Steven L. Basta, also known as Steve, M.B.A., serves as Chief executive Officer, President and Director at Phathom Pharmaceuticals, Inc. from April 1, 2025. He is Director of DermBiont, Inc. He served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | no data | US$266.34k | 1.72% $ 21.1m | |
| Co-Founder | no data | US$2.04m | 1.31% $ 16.1m | |
| CEO, President & Director | less than a year | no data | 0.16% $ 2.0m | |
| Chief Financial & Business Officer | less than a year | no data | no data | |
| Senior VP and Head of Sales | less than a year | no data | no data | |
| VP of Finance & Principal Accounting Officer | less than a year | no data | no data | |
| Director of Business Development & Investor Relations | no data | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | 0.014% $ 167.2k | |
| Senior Vice President of Marketing & Analytics | less than a year | no data | no data | |
| Chief People Officer | 1.7yrs | no data | no data | |
| Chief Medical Officer | 6yrs | no data | no data |
Experienced Management: PHAT's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | no data | 0.16% $ 2.0m | |
| Independent chairman of the Board | 6.3yrs | US$331.34k | 0.041% $ 506.5k | |
| Independent Director | 6.3yrs | US$287.17k | 0.027% $ 337.1k | |
| Independent Director | 3.3yrs | US$267.14k | 0.045% $ 555.0k | |
| Independent Director | 3.7yrs | US$283.84k | 0.080% $ 985.6k | |
| Director | less than a year | no data | 0.030% $ 363.1k | |
| Independent Director | 6yrs | US$279.67k | 0.16% $ 1.9m | |
| Independent Director | 5.8yrs | US$283.84k | 0.027% $ 337.1k |
Experienced Board: PHAT's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 13:59 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Phathom Pharmaceuticals, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jenna Davidner | Barclays |
| null null | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |